Author

Matthew A. Ciorba 1

1 Washington University School of Medicine,St. Louis,United States

Combined ileal biomarkers can discriminate responders from non-responders to vedolizumab therapy in Crohn's disease

Mark Osterman, Elisabeth M. Davis, Ilyssa O. Gordon, Kate Simpson, Matthew A. Ciorba, Sarach C. Glover, Bincy P. Abraham, Eric Yee,, Felicia Allard, Brian Claggett, Bo Shen, Thaddeus S. Stappenbeck, Julia Liu

PREDICTING CLINICAL RESPONSE TO VEDOLIZUMAB THERAPY IN CROHN'S DISEASE WITH MUCOSAL BIOMARKER OF INNATE IMMUNE ACTIVATION

Mark T. Osterman, Ilyssa O. Gordon, Matthew A. Ciorba, Sarah C. Glover, Bincy P. Abraham, Elisabeth M. Davis, Freeha Khan, Kennedy Young, Xueyan Guo, Eric U Yee, Felicia Allard, Brian Claggett, Bo Shen, Julia Liu

Tofacitinib for the treatment of ulcerative colitis: an update on the analysis of malignancy rates from the UC clinical programme

Gary R. Lichtenstein, Matthew A. Ciorba, Gerhard Rogler, Daniel Quirk, Andrew J. Thorpe, Ronald D. Pedersen, Nervin Lawendy, Gary Chan, Julian Panés

TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN UPDATE ON THE ANALYSIS OF MALIGNANCY RATES FROM THE ULCERATIVE COLITIS CLINICAL PROGRAMME AS OF MAY 2019

Gary Lichtenstein, Matthew A. Ciorba, Gerhard Rogler, Ala I. Sharara, Nancy Sunna, Rajiv Mundayat, Donna T Judd, Nervin Lawendy, Julian Panés

Item 1 - 4 / 4
1